依奇珠单抗治疗中重度银屑病疗效及安全性回顾分析

Efficacy and safety of ixekizumab for moderate to severe psoriasis

目的:回顾性分析依奇珠单抗治疗中重度银屑病的疗效及安全性。方法:收集2021年8月至2023年7月在我院接受使用依奇珠单抗治疗的76例中重度银屑病患者临床资料。依奇珠单抗的初始剂量为160 mg皮下注射,分2次注射,注射后剂量调整为80 mg,于2、4、6、8、10、12周皮下注射,最后改为80 mg维持剂量,每4周一次。分析患者治疗前后的病情改善情况和患者治疗过程中不良反应发生情况。结果:76例银屑病患者中T-spot试验阳性8例,轻度肝功能异常5例,轻度肾功能异常2例。经依奇珠单抗治疗后,银屑病面积及严重程度指数(psoriasis area and severity index,PASI)75改善的患者占100%(76/76),PASI 90改善的患者占89.5%(68/76),PASI 100改善的患者占59.2%(45/76)。依奇珠单抗对银屑病关节炎及银屑病甲的疗效显著。治疗中发生的不良反应有注射部位红肿8例,风团样瘙痒性皮疹2例,急性咽喉炎1例,口腔溃疡1例,局限性湿疹3例,面颈部瘙痒性红斑1例,上呼吸道感染5例。结论:依奇珠单抗治疗中重度银屑病具有良好的疗效及安全性。

Objective:To explore the efficacy and safety of ixekizumab for moderate to severe psoriasis.Methods:The clinical data of 76 patients with moderate to severe psoriasis who received ixekizumab treatment in our department from August 2021 to July 2023 were collected.The initial dose of Lxekizumab was subcutaneous injection at 160 mg twice.After injection,the dose was adjusted to 80 mg subcutaneously at 2,4,6,8,10,12 weeks,and finally to 80 mg for maintenance dose once every four weeks.The improvement of patients’condition before and after treatment and the occurrence of adverse reactions during the treatment were analyzed.Results:Among 76 patients with psoriasis,8 cases were positive for T-spot Test,5 cases were mild abnormal liver function,and 2 cases were mild abnormal renal function.After treatment with Lxekizumab,100%(76/76)of patients with Psoriasis Area and Severity Index(PASI)75 improved,89.5%(68/76)of patients with PASI 90 improved,and 59.2%(45/76)of patients with PASI 100 improved.The curative effect of Lxekizumab on psoriatic arthritis and psoriatic nail was remarkable.There were 8 cases of injection site swelling,2 cases of pruritus,1 case of acute pharyngitis,1 case of oral ulcer,3 cases of local eczema,1 case of pruritus erythema and 5 cases of upper respiratory tract infection.Conclusion:Ixekizumab in the treatment of moderate to severe psoriasis can get good efficacy and safety.